Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
$346,435A. McGarry Houghton · Fred Hutchinson Cancer Center · P50 · FY2023 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
$346,435A. McGarry Houghton · Fred Hutchinson Cancer Center · P50 · FY2022 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC
$346,435A. McGarry Houghton · Fred Hutchinson Cancer Research Center · P50 · FY2019 · CA
Targeting immune stroma interactions in pancreatic cancer
$346,416Gregory B. Lesinski · Emory University · R01 · FY2020 · CA
CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
$346,410Sloan-Kettering Institute For Cancer Res · R01 · FY2002 · CA
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC
$346,329Xingming Deng · Emory University · P50 · FY2023 · CA
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Bjoern F Lillemeier · Salk Institute For Biological Studies · R01 · FY2018 · GM
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Ye Zheng · Salk Institute For Biological Studies · R01 · FY2020 · GM
Investigating the interplay of structural, molecular and spatial mechanisms that control SHP2 activity downstream of PD1
$346,320Bjoern F Lillemeier · Salk Institute For Biological Studies · R01 · FY2019 · GM
Project 2: Neo-antigen Vaccines for Pancreatic and Colorectal Cancers
$346,165Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2020 · CA
Role of the macrophage derived XL313 epitope in angiogenesis and tumor growth
$346,144Peter C. Brooks · Mainehealth · R01 · FY2019 · CA
Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming in single cancer cells
$345,940Raul Rabadan · Columbia University Health Sciences · U54 · FY2016 · CA
Re-activating Memory T Cells in the Microenvironment of Human Tumors
$345,888Richard B Bankert · State University Of New York At Buffalo · R01 · FY2009 · CA
Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunity
$345,885Hu Zeng · Mayo Clinic Rochester · R01 · FY2022 · AR
Re-activating Memory T Cells in the Microenvironment of Human Tumors
$345,843Richard B Bankert · State University Of New York At Buffalo · R01 · FY2010 · CA
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
$345,824Robert M Prins · University Of California Los Angeles · P50 · FY2019 · CA
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
$345,823Linda M Liau · University Of California Los Angeles · P50 · FY2021 · CA
Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming in single cancer cells
$345,747Raul Rabadan · Columbia University Health Sciences · U54 · FY2017 · CA
Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming in single cancer cells
$345,604Raul Rabadan · Columbia University Health Sciences · U54 · FY2020 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer
$345,600Wenyi Wei · Beth Israel Deaconess Medical Center · R01 · FY2009 · GM
Rational Sequencing of PD-1 and CTLA-4 Antibodies in Metastatic Melanoma
$345,579Jeffrey S Weber · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2013 · CA
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy
$345,558Jessica E Thaxton · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
$345,528Richard G Vile · Mayo Clinic Rochester · R01 · FY2024 · CA
Targeting immune stroma interactions in pancreatic cancer
$345,477Gregory B. Lesinski · Emory University · R01 · FY2021 · CA
First in Human Trials of ProAgio, a Cytotoxin
$345,447Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA